Healthcare >> CEO Interviews >> May 22, 2001

Anna Gluskin – Generex Biotechnology Corporation (gnbt)

ANNA E. GLUSKIN is the President and Chief Executive Officer of Generex Biotechnology Corporation. Ms. Gluskin has held this senior position in the company since its inception. Within this capacity, Ms. Gluskin plans, co-ordinates and manages the business development activities of the company, leading up to the timely development of new and improved product processes. She provides leadership throughout the company and directs most of her efforts towards seeking new opportunities wherein Generex's platform technologies may effectively be utilized. Ms. Gluskin has spent much of her 25-year career within the global market in the areas of finance. She has successfully negotiated agreements for various ventures and developments worldwide. Since 1990, Ms. Gluskin has worked on a number of medically related projects where she has developed her skills in managing and directing several healthcare development groups. Profile
TWST: Could we start out by you giving us a brief overview of Generex?

Ms. Gluskin: The company has a proprietary platform technology which

allows for the buccal delivery of large molecules,